China Isotope subsidiary partners with Novartis for prostate cancer therapy

China Isotope & Radiation Corporation's subsidiary, HTA Co., Ltd. (HTA), has officially entered into a Commercial Cooperation Agreement with Novartis Pharma Technology (Zhejiang) Co., Ltd. (Novartis). This agreement focuses on Pluvicto (lutetium [177Lu] vipivotide tetraxetan injection), the first and only approved prostate-specific membrane antigen (PSMA)-targeted radioligand therapy in China for advanced prostate cancer.

The partnership leverages HTA's extensive operational experience in radiopharmaceuticals to provide customized Pluvicto product supply and related solutions to medical institutions and patients. This collaboration is expected to enhance patient access to a therapeutic option designed to prolong survival and improve quality of life.

The board of China Isotope & Radiation Corporation confirmed that Novartis and its beneficial owners are independent third parties and the agreement does not constitute a notifiable or connected transaction under listing rules. Shareholders and potential investors are advised to exercise caution.